Document:

msi33112ex102a01

   CL2 Page 1   ACE American Insurance Company   (A Stock Company)   Philadelphia, PA    (Herein called We, Us, Our) Summary of Benefits                     Accident Benefits for Motorola Solutions, Inc.      Policy Term:  January 1, 2012 to January 1, 2013      You are a Covered Person and eligible for coverage under the plan, if you are in the eligible class defined below. For benefits   to be payable the Policy must be in force, the required premium must be paid and you must be engaging in one of the   Covered Activities described below. If you are not in Active Service on the date your insurance would otherwise be effective,   it will go into effect on the date you return to Active Service.      Class Description: All Non-employee Directors of the Policyholder.      Your Dependents (your lawful spouse and unmarried children, subject to the age limits shown in the Policy) are also covered,   if they are traveling with you.      Period of Coverage: You will be insured on the later of the Policy Effective Date or the date that you become eligible. Your   coverage will end on the earliest of the date: 1) the Policy terminates; 2) you are no longer eligible; or 3) the period ends for   which the required premium is paid. Dependents coverage will end on the earliest of the date: 1) he or she is no longer a   Dependent; 2) your coverage ends; or 3) the period ends for which the required premium is paid.      Covered Activities      Exposure & Disappearance - Coverage includes exposure to the elements after the forced landing, stranding, sinking, or   wrecking of a vehicle in which you were traveling.  You are presumed dead if you are in a vehicle that disappears, sinks, or is   stranded or wrecked on a trip covered by this Policy; and the body is not found within one year of the Covered Accident.      24-Hour Coverage - We will pay the benefits described in the Policy when you suffer a Covered Accident any time while   insured by the Policy. Unless otherwise specified, We will pay benefits only once for a Covered Accident.      Business Travel - The Covered Accident must take place while traveling: 1) on business for the Policyholder; and 2) in the   course of the Policyholder’s business. This coverage does not include commuting between home and the place of work.      This coverage will start at the actual start of the trip. It does not matter whether the trip starts at your home, place of work, or   other place. It will end on the first of the following dates to occur: 1) the date you return to your home; 2) the date you return   to your place of work; or 3) the date your Personal Deviation is more than 14 day(s).  “Personal Deviation” means: 1) an   activity that is not reasonably related to the Policyholder’s business; and 2) not incidental to the purpose of the trip.      Felonious Assault - The Covered Accident must: 1) take place on the Policyholder’s premises;  2) be in the course of your   job; and, 3) be caused by or result directly and independently from a Felonious Assault, as defined below.  The assault must   be inflicted by a person other than another person covered by the Policy, your Immediate Family Member, or Household   Member. A police report detailing the Felonious Assault must be provided.      The Covered Accident must occur during any of the following: 1) actual or attempted robbery or holdup; or 2) actual or   attempted kidnapping; or 3) any other type of intentional assault that is a crime classified as a felony by the governing statute   or common law in the state where the assault occurred. “Felonious Assault” means a criminal act or an act of physical   violence against a person covered by this Policy. “Immediate Family Member” means your parent, sister, brother, husband,   wife, or children. “Household Member” means a person who maintains residence at the same address as you.      Hijacking and Air Piracy - The Covered Accident must: 1) take place during the: a) hijacking of an Aircraft; b) air piracy; or   c) unlawful seizure or attempted seizure of an Aircraft; and 2) take place while you are in the course of the Policyholder’s   business.  Coverage begins with the onset of the hijacking or air piracy and continues while you are subject to the control of   the person or persons responsible for the hijacking/air piracy and during travel directly to your home or scheduled   destinations.  “Hijacking” or “Air Piracy,” as used here, means the unlawful seizure or wrongful exercise of control of an   aircraft or conveyance, or the crew thereof, in which you are traveling solely as a passenger.        

 

CL2 Page 2   Owned, Leased, or Controlled Aircraft - The Covered Accident must take place while: 1) you are riding in, or getting on or   off of, a covered aircraft; or 2) as a result of you being struck by a covered aircraft. 3) away from the Policyholder's premises   in your city of permanent assignment; 4) on business for the Policyholder; and 5) in the course of the Policyholder's business.       This coverage will start at the actual start of the trip. It does not matter whether the trip starts at your home, place of work, or   other place. It will end on the first of the following dates to occur: 1) the date you return to your home; 2) the date you return   to your place of work; or 3) the date your Personal Deviation is more than 14 day(s).  “Personal Deviation” means: 1) an   activity that is not reasonably related to the Policyholder's business; and 2) not incidental to the purpose of the trip. An aircraft   will be deemed “controlled” by the Policyholder if the Policyholder may use it for more than 10 straight days, or more than 15   days in any year.      Aircraft Restrictions - If the Covered Accident happens while you are riding in, or getting on or off of, an aircraft, We will pay   benefits, but only if: 1) you are riding as a passenger only, and not as a pilot or member of the crew (except as provided by   the Policy); and 2) the aircraft has a valid certificate of airworthiness; and 3) the aircraft is flown by a pilot with a valid license;   and  4) the aircraft is not being used for: (i) crop dusting, spraying, or seeding; firefighting; skywriting; skydiving or hang   gliding; pipeline or power line inspection; aerial photography or exploration; racing, endurance tests, stunt or acrobatic flying;   or (ii) any operation which requires a special permit from the FAA, even if it is granted (this does not apply if the permit is   required only because of the territory flown over or landed on). 5) the aircraft is a military transport aircraft flown by the U.S.   Military Airlift Command (MAC), or similar air transport service of another country.      Relocation - The Covered Accident must take place while you are traveling on a Relocation Trip at the expense and   direction of the Policyholder. “Relocation Trip” means a trip in connection with your transfer or proposed transfer by the   Policyholder to a new worksite.      This coverage will start at the actual start of the trip. It does not matter whether the trip starts at your home, place of work, or   other place. It will end on the first of the following dates to occur: 1) the date you return to your home; 2) the date you return   to your place of work; or 3) the date your Personal Deviation is more than 14 day(s).  “Personal Deviation” means: 1) an   activity that is not reasonably related to the Policyholder’s business; and 2) not incidental to the purpose of the trip.      Terrorism - The Covered Accident must: 1) take place while you are on the Policyholder’s premises, or in the course of a)   the Policyholder’s business and/or b) your job; and, 2) be caused by or results directly and independently from Terrorism or   Terrorist Act, as defined below.      “Terrorism or Terrorist Acts” means an activity that: 1) involves any violent act or any act dangerous to human life and that   threatens or causes Injury to persons; and 2) appears to be in any way intended to: a) intimidate or coerce a civilian   population; or b) disrupt any segment of a nation's economy; or c) influence the policy of a government by intimidation or   coercion; or d) affect the conduct of a government by mass destruction, assassination, kidnapping, or hostage taking; or e)   respond to governmental action or policy. It includes any incident declared to be an act of terrorism by an official, department,   or agency that has been specifically authorized by federal statute to make such a determination. It shall also include the use   of any nuclear weapon or device or the emission, discharge, dispersal, release, or escape of any solid liquid or gaseous   chemical or biological agent.          Description of Benefits      Aggregate Limit - We will not pay more than per Covered Accident: $15,000,000; for all losses.  If, in the absence of this   provision, We would pay more than this amount for all losses under the policy, then the benefits payable to each person with   a valid claim will be reduced proportionately.      Accidental Death and Dismemberment Benefits - If your Injury results, within 365 days from the date of a Covered   Accident, in any one of the losses shown below, We will pay the Benefit Amount shown below for that loss.  Your Principal   Sum is $500,000.  Your spouse’s Principal Sum is $50,000.  Your child’s Principal Sum is $25,000.  If multiple losses occur,   only one Benefit Amount, the largest, will be paid for all losses due to the same Covered Accident.        Schedule of Covered Losses   Covered Loss Benefit Amount       Life ........................................................................................................................100% of the Principal Sum   Two or more Members..........................................................................................100% of the Principal Sum   Quadriplegia..........................................................................................................100% of the Principal Sum   One Member...........................................................................................................50% of the Principal Sum     

 

CL2 Page 3   Hemiplegia ..............................................................................................................75% of the Principal Sum   Paraplegia...............................................................................................................75% of the Principal Sum   Thumb and Index Finger of the Same Hand ..........................................................25% of the Principal Sum       “Quadriplegia” means total Paralysis of both upper and lower limbs.  “Hemiplegia” means total Paralysis of the upper and   lower limbs on one side of the body.  “Paraplegia” means total Paralysis of both lower limbs or both upper limbs.  “Paralysis”   means total loss of use.  A Doctor must determine the loss of use to be complete and not reversible at the time the claim is   submitted.      “Member” means Loss of Hand or Foot, Loss of Sight, Loss of Speech and Loss of Hearing.  “Loss of Hand or Foot” means   complete Severance through or above the wrist or ankle joint.  “Loss of Sight” means the total, permanent Loss of Sight of   one eye. “Loss of Speech” means total and permanent loss of audible communication that is irrecoverable by natural,   surgical or artificial means.  “Loss of Hearing” means total and permanent Loss of Hearing in both ears that is irrecoverable   and cannot be corrected by any means. “Loss of a Thumb and Index Finger of the Same Hand” means complete Severance   through or above the metacarpophalangeal joints of the same hand (the joints between the fingers and the hand).    “Severance” means the complete separation and dismemberment of the part from the body.      Coma Benefit - We will pay 1% of the Principal Sum per month up to 11 months and thereafter in a lump sum of 100% of the   Principal Sum if you become Comatose within 31 days of a Covered Accident and remain in a Coma for at least 31 days. We   reserve the right, at the end of the first 31 days of Coma, to require proof that you remain Comatose.  This proof may include,   but is not limited to, requiring an independent medical examination at Our expense. Monthly payments will end on the first of   the following dates: 1) the end of the month in which you die; 2) the end of the 11th month for which this benefit is payable; 3)   the end of the month in which you recover from the Coma.        You are deemed “Comatose” or in a “Coma” if you are in a profound stupor or state of complete and total unconsciousness,   as the result of a Covered Accident.      Disability Benefit (Permanent Total Disability) (Does not apply to Dependents) - We will pay 100% of the Principal Sum   if you are under age 70 and Permanently Totally Disabled as a direct result of, and from no other cause but, a Covered   Accident.  Permanent Total Disability must begin within 365 days from the date of your Covered Accident.  Disability Benefits   will begin when: 1) the applicable Benefit Waiting Period of 365 days is satisfied; and 2) you provide satisfactory proof of   Permanent Total Disability to Us.        “Total Disability” or “Totally Disabled” means, due to an Injury from a Covered Accident, you: 1) if employed, cannot do any   work for which you are, or may become, qualified by reason of education, experience or training; and 2) if not employed,   cannot perform the normal and customary activities of a healthy person of like age and sex. “Permanent Total Disability” or   “Permanently Totally Disabled” means you are Totally Disabled and are expected to remain so disabled, as certified by a   Doctor, for the rest of your life. Permanent Total Disability must be the result of the same Covered Accident that caused the   Total Disability.      Emergency Medical Benefits - We will pay up to $10,000 for Covered Expenses incurred for emergency medical services to   treat you if you: 1) suffer a Medical Emergency during the course of a Trip; and 2) are traveling 100 miles or more away from your   place of permanent residence.  Covered Expenses include expenses for guarantee of payment to a medical provider, Hospital   or treatment facility.  Benefits for these Covered Expenses will not be payable unless the charges incurred: 1) are Medically   Necessary and do not exceed the charges for similar treatment, services or supplies in the locality where the expense is incurred;   and 2) do not include charges that would not have been made if there were no insurance.  Benefits will not be payable unless We   authorize in writing, or by an authorized electronic or telephonic means, all expenses in advance, and services are rendered by   Our assistance provider.      Emergency Medical Evacuation Benefit - We will pay 100% of Covered Expenses incurred for your medical evacuation if   you: 1) suffer a Medical Emergency during the course of the Trip; 2) require Emergency Medical Evacuation; and 3) are   traveling 100 miles or more away from your place of permanent residence.  Covered Expenses; 1) Medical Transport:   expenses for transportation under medical supervision to a different hospital, treatment facility or to your place of residence   for Medically Necessary treatment in the event of your Medical Emergency and upon the request of the Doctor designated by   Our assistance provider in consultation with the local attending Doctor.  2) Dispatch of a Doctor or Specialist: the Doctor’s or   specialist’s travel expenses and the medical services provided on location, if, based on the information available, your   condition cannot be adequately assessed to evaluate the need for transport or evacuation and a doctor or specialist is   dispatched by Our service provider to your location to make the assessment.  3) Return of Dependent Child(ren): expenses   to return each Dependent child who is under age 18 to his or her principal residence if a) you are age 18 or older; and b) you   are the only person traveling with the minor Dependent child(ren); and c) you suffer a Medical Emergency and must be     

 

CL2 Page 4   confined in a Hospital.  4) Escort Services: expenses for an Immediate Family Member or companion who is traveling with   you to join you during your emergency medical evacuation to a different hospital, treatment facility or your place of residence.      Benefits for these Covered Expenses will not be payable unless: 1) the Doctor ordering the Emergency Medical Evacuation   certifies the severity of your Medical Emergency requires an Emergency Medical Evacuation; 2) all transportation   arrangements made for the Emergency Medical Evacuation are by the most direct and economical conveyance and route   possible; 3) the charges incurred are Medically Necessary and do not exceed the Usual and Customary Charges for similar   transportation, treatment, services or supplies in the locality where the expense is incurred; and 4) do not include charges   that would not have been made if there were no insurance.        Benefits will not be payable unless We authorize in writing, or by an authorized electronic or telephonic means, all expenses   in advance, and services are rendered by Our assistance provider.  In the event you refuse to be medically evacuated, we   will not be liable for any medical expenses incurred after the date medical evacuation is recommended.      Repatriation of Remains Benefit - We will pay 100% of Covered Expenses for preparation and return of your body to your   home if you die as a result of a Medical Emergency while traveling 100 miles or more away from your place of permanent   residence.  Covered expenses include: 1) expenses for embalming or cremation;  2) the least costly coffin or receptacle   adequate for transporting the remains; 3) transporting the remains; and 4) Escort Services which include expenses for an   Immediate Family Member or companion who is traveling with you to join your body during the repatriation to your place of   residence.      All transportation arrangements must be made by the most direct and economical route and conveyance possible and may   not exceed the Usual and Customary Charges for similar transportation in the locality where the expense is incurred.    Benefits will not be payable unless We authorize in writing, or by an authorized electronic or telephonic means, all expenses   in advance, and services are rendered by Our assistance provider.      Special Adaptation Benefit - We will pay 10% of the Principal Sum up to $10,000, if you suffer a “Presumptive Disability”   and require a special housing adaptation or a special Vehicle to accommodate the disability. Benefits will not be payable   unless your Doctor certifies them as necessary.  “Presumptive Disability” means We will presume you are Totally Disabled if   you suffer the complete and irrecoverable loss of sight of both eyes, speech, hearing in both ears, or of any two limbs, hands   or feet, provided the loss occurs within one year of the Covered Accident.  “Vehicle” means a private passenger land motor   vehicle.  It includes automobiles, vans, and four wheel drive vehicles. It does not include a vehicle used for farming,   commercial business, racing or any type of competitive speed event.      Special Counseling Benefit - We will pay $100 per session for up to 10 counseling sessions for mental health counseling to   assist you in dealing with a Covered Loss, if you suffer a Covered Loss for which benefits are payable; and obtain mental   health counseling.  The Maximum Amount for this benefit is $1,000 per Covered Loss.      Exclusions and Limitations: We will not pay benefits for any loss or Injury that is caused by, or results from:     intentionally self-inflicted Injury.    suicide or attempted suicide.    war or any act of war, whether declared or not (except as provided by the Policy).    a Covered Accident that occurs while on active duty service in the military, naval or air force of any country or   international organization. Upon Our receipt of proof of service, We will refund any premium paid for this time. Reserve or   National Guard active duty training is not excluded unless it extends beyond 31 days.    sickness, disease, bodily or mental infirmity, bacterial or viral infection, or medical or surgical treatment thereof, except   for any bacterial infection resulting from an accidental external cut or wound or accidental ingestion of contaminated food.    piloting or serving as a crewmember in any aircraft (except as provided by the Policy).    commission of, or attempt to commit, a felony.      This insurance does not apply to the extent that trade or economic sanctions or regulations prohibit Us from providing   insurance, including, but not limited to, the payment of claims.      War Risk Coverage:  We will pay benefits for Covered Losses due to Covered Accidents resulting from war or acts of   war anywhere in the world, except the following countries:      the United States    The Covered Person’s Home Country    The Covered Person’s Country of Permanent Assignment      The war exclusion is deleted to the extent coverage is provide by the terms and conditions of War Risk Coverage.        

 

CL2 Page 5   “Home Country” means a country from which you hold a passport. If you hold passports from more than one Country,   your Home Country will be the country that you declared to Us in writing as your Home Country.      “Country of Permanent Assignment” means a country, other than your Home Country, in which the Policyholder requires you   to work for a period of time that exceeds 180 continuous days.      We will not pay more than $15,000,000 per occurrence for war risk benefits.  This limit shall apply to Injuries sustained from   all acts of war in a consecutive 72-hour period.  If but for this limit We would pay more than $15,000,000, then the benefits   We will pay to each Covered Person will be reduced in the same proportion, so that the total amount We will pay for war risk   coverage is $15,000,000.         Definitions: “Covered Accident” means an accident that occurs while coverage is in force for you and results directly of all   other causes in a loss or Injury covered by the Policy for which benefits are payable. “Covered Person” means any eligible   person for whom the required premium is paid. “Injury” means accidental bodily harm sustained by you that results directly   from all other causes from a Covered Accident. All injuries sustained by one person in any one Covered Accident, including   all related conditions and recurrent symptoms of these injuries, are considered a single Injury. “Medical Emergency” means   a condition caused by an Injury or Sickness that manifests itself by symptoms of sufficient severity that a prudent lay person   possessing an average knowledge of health and medicine would reasonably expect that failure to receive immediate medical   attention would place the health of the person in serious jeopardy. “Sickness” means an illness, disease or condition that   causes a loss for which you incur medical expenses while covered under this Policy.  All related conditions and recurrent   symptoms of the same or similar condition will be considered one Sickness. “Trip” means travel by air, land, or sea from your   Home Country. “We, Our, Us” means the insurance company underwriting this insurance or its authorized agent.      You must notify ACE USA within 90 days of an Accident or Loss. If notice cannot be given within that time, it must be given   as soon as reasonably possible. This notice should identify you, your employer, and the Policy Number.    Policy Number: ADD N04156870R, Underwritten by ACE American Insurance Company, 436 Walnut Street, Philadelphia, PA   19106       Contact Information: For customer service, eligibility verification, plan information, or to file a claim, contact: ACE   USA at 800-336-0627 (from inside the U.S.) or 302-476-6194 (from outside the U.S.); fax 302-467-6154 for claims or   inquiries or e-mail diane.basa@acegroup.com. Mail claims to: ACE USA, PO Box 15417, Wilmington, DE 19850. For   medical evacuation, repatriation, or other assistance services call: Europ Assistance at 800-243-6124 (inside the   U.S.) or call collect 202-659-7803 (from outside the U.S.) or e-mail OPS@europassistance-usa.com.       To access ACE’s Travel Assistance Website go to www.acetravelassistance.com and enter your user ID and   password (shown on your Travel Assistance ID card).       Travel Assistance Services: In addition to the insurance protection provided by this plan, ACE USA has arranged with   Europ Assistance USA to provide you with access to its travel assistance services around the world. These services include:    Medical Assistance including referral to a doctor or medical specialist, medical monitoring when you are hospitalized,   emergency medical evacuation to an adequate facility, medically necessary repatriation, and return of mortal remains.    Personal Assistance including pre-trip medical referral information and while you are on a trip: emergency medication,   embassy and consular information, lost document assistance, emergency referral to a lawyer, translator or interpreter   access, medical benefits verification, and medical claims assistance.    Travel Assistance including emergency travel arrangements, arrangements for the return of your traveling companion or   dependents, and vehicle return.     Access to a secure, web-based system for tracking global threats and health or location based risk intelligence.    Crisis hotline and on the ground security assistance to help address safety concerns or to secure immediate assistance   while traveling.        When you call, please be prepared with the following information: 1) name of caller, phone number, fax number, and   relationship to the Covered Person; 2) Covered Person’s name, age, sex, and the policy number for your insurance plan, and   your Plan Number (01AH585); 3) a description of the insured’s condition; 4) name, location, and telephone number of the   hospital or other service provider; and 5) other insurance information including health insurance, workers’ compensation, or   auto insurance if the insured was involved in an accident.      This information provides you with a brief outline of the services available to you. These services are subject to the terms and   conditions of the Policy under which you are insured. A third party vendor may provide services to you. Europ Assistance   makes every effort to refer you to appropriate medical and other service providers. It is not responsible for the quality or   results of service provided by independent providers. In all cases, the medical provider, facility, legal counsel, or other     

 

CL2 Page 6   professional service provider suggested by Europ Assistance are not employees or agents of Europ Assistance and the   choice of provider is yours alone. Europ Assistance assumes no liability for the services provided to you under this   arrangement, nor is it liable for any negligence or other wrongful acts or omissions of any of the legal or health care   professionals providing services to you. Travel assistance services are not available if your coverage under the Policy   providing insurance benefits is not in effect.       This Description of Coverage is a brief description of the important features of the insurance plan. It is not a contract of   insurance. The terms and conditions of coverage are set forth in the Policy issued to your employer. The Policy is subject to   the laws of the state in which it was issued. Coverage may not be available in all states or certain terms or conditions may be   different if required by state law. Please keep this information as a reference.prbm_ex101.htm

EXHIBIT 10.1

 

COLLABORATIVE AGREEMENT

 

This Collaborative Agreement (the "Agreement") is made between The University of Texas at El Paso, ("University"), an institution of The University of Texas System ("System"), and Premier Biomedical, Inc., a corporation with its place of business at: 10805 Fallen Leaf Lane Port Richey, FL 34668 ("Company").

 

RECITALS

 

A. University and Company (hereafter collectively called “parties”) are each pursuing various aspects of research in the field of Apheresis Selective Depletion of Small Reactive Molecules and Pathogens that Involves a Novel Treatment of the Pathophysiologic Basis of Diseases such as Alzheimer's Disease, Traumatic Brain Injury (TBI), Chronic Pain Syndrome, Fibromyalgia, Multiple Sclerosis, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease), Blood Sepsis, Cancer, Heart Attacks and Strokes" ("Field").

 

B. Parties desire to collaborate for the purpose of further developing the technology within the Field and Company is willing to sponsor University's research.

 

C. Company desires to obtain certain rights to patents and technology resulting from the research.

 

D. University is willing to grant certain rights to patents and technology that may result from the research collaboration.

 

NOW THEREFORE, in consideration of the mutual covenants and promises herein contained, the Parties agree as follows:

 

1. EFFECTIVE DATE

 

This Agreement shall be effective as of May 1, 2012 (the "Effective Date").

 

2. RESEARCH PROGRAM

 

	
a.   

	
All Research Programs arising out of this Agreement will be negotiated separately (hereafter referred to as “R&D Program Agreement”) in regards to scope of work, funding/costs, and performance period.  Company must approve in writing each R&D Program prior to University conducting any research utilizing Company’s Background IP. University will use its own and other facilities, as appropriate, and its reasonable best efforts to conduct R&D Programs in the Field. University’s primary R&D programs are under the direction of Dr. Robert Kirken or his successor as mutually agreed to by the parties (the "Principal Investigator"). Initially, the R&D Program will involve research dealing with Alzheimer's, TBI and Cancer treatments. Afterwards, other diseases will be addressed by mutual agreement of the University and the Company.  The initial R&D Program will be detailed within ninety (90) days after the Effective Date.

  

1

  

 

	
b.   

	
The Research Program shall be carried out from the Effective Date through and including five (5) years (the "Research Program Term"). The parties may extend the Research Program under mutually agreeable terms.

	
 c.  

	
Company understands that University's primary mission is education and advancement of knowledge and R&D Programs will be designed to carry out that mission. The design of R&D Programs shall be determined by mutual collaboration between the parties. The conduct of the R&D Program and any related outcomes shall be at the discretion of the University. University does not guarantee specific results.

 

	
d.  

	
Company understands that University may be involved in similar research through other researchers on behalf of itself and others. University shall be free to continue such research provided that it is conducted separately and by different investigators from R&D Programs, and Company shall not gain any rights via this Agreement to other research.

	
e.  

	
University does not guarantee that any intellectual property will result from Research Program, that any resulting intellectual property will be free of dominance by other's rights, including rights based on inventions made by other inventors in the System independently of the Research Program.

 

3. COMPENSATION

 

	
a.  

	
Company will pay the University an amount equal to its expenditures and University’s negotiated overhead Facility and Administration (F&A) cost in conducting Research Programs.  Each R&D Program Agreement will consist of a budget reflecting financial consideration along with specifically designed project objectives and period of performance. Each R&D Program Agreement will be designed, proposed, negotiated, and finalized within sixty (60) calendar days after development of the scope of work of the specific project. Each R&D Program Agreement will be supported by an initial upfront payment of $3,000 from Company which shall be made within thirty (30) calendar days upon execution of each negotiated R&D Program Agreement. Subsequent payments shall be made on costs detailed in the Budget within thirty (30) calendar days after receipt of properly documented invoice issued by appropriate University authorities, where the initial upfront payment will be credited to Company.

 

	
b.  

	
Company will make payments to The University of Texas at El Paso, referencing the Principal Investigator and R&D Program title, to the following address: Office of Research and Sponsored Projects, Administration Building, Room 209, El Paso, Texas 79968.

  

2

  

 

	
c.  

	
The Principal Investigator may transfer funds within the budget as needed without Company's approval so long as the scope of work under the R&D Program remains unchanged. After termination in compliance with the provisions of Section 11, University will return to Company all uncommitted and unexpended funds. University shall retain title to all equipment purchased and/or fabricated by it with funds provided by Company under this Agreement, subject to any express restrictions agreed to in writing between the Parties.

 

4. COMMUNICATION AND REPORTS

 

	
a.  

	
The Parties designated representative for communications shall be Dr. Robert Kirken for University and Dr. Mitchell Felder for Company, or any other persons the Parties may designate in writing and with mutual consent ("Designated Representative").

	
b.  

	
Parties agree to form a committee for periodic Intellectual Property review. The committee will meet from time to time as appropriate, to review Intellectual Property.  The committee shall be composed of Dr. Mitch Felder, a representative of the Company (currently Mr. William Hartman), three  (3)  representatives  from  the  University  (currently  Dr.  Robert  A. Kirken and Dr. Gary E. Williams; third representative to be determined) and the DoD (currently LTC Dr. Shawna Scully).   Committee members may change from time to time, depending on subject matter expertise and need to know.

 

	
c.  

	
The University and Company will keep one another informed of the results of the work performed in connection with R&D Program, where each R&D Program Agreement will detail specific progress reporting requirements. The Principal Investigator of this Collaboration Agreement will submit an annual written summary progress and financial report of the R&D completed each year of this Agreement and submit a comprehensive final report within one hundred twenty (120) days after expiration or termination of the Agreement.

 

5. PUBLICITY

 

All public relations statements by either party relative to this Collaborative Agreement must have written approval, signed by each partys authorizing official prior to release, except as required by the Texas Public Information Act or other law or regulation. University, however, may acknowledge Company's support of R&D Program Agreements in scientific or academic publications or communications without Company's prior approval.In any such unrestricted public relation statements, the parties shall describe the scope and nature of their participation accurately and appropriately.

  

3

  

 

6. PUBLICATION AND ACADEMIC RIGHTS

 

	
a.  

	
The Principal Investigator has the right to publish or otherwise publicly disclose information gained in the course of an R&D Program. In order to avoid loss of patent rights as a result of premature public disclosure of patentable information, University will submit any prepublication materials to Company for review and comment at leastsixty (0) calendar days prior to planned submission for publication. Company shall notify University within thirty (30) days of receipt of such materials whether they describe any inventions or discoveries subject to the parties' rights under Section 8 of this Collaborative Agreement.University shall have the final authority to determine the scope and content of any publications but will respect Company’s review and comments of publication materials regarding premature public disclosure of patentable information.

	
  b.  

	
University investigators may discuss R&D Programs with other investigators for scientific or research purposes but shall not reveal information which is Company's Confidential Information under Article 7. If any joint inventions result from such discussion, University shall grant Company the rights set forth in Section 8, to the extent these are not in conflict with obligations to another party as a result of the involvement of the other investigator(s). In this latter case, University shall, in good faith, exercise reasonable efforts to enable Company to obtain rights to the joint invention.

 

7. CONFIDENTIAL INFORMATION

 

	
a.  

	
The parties may wish to disclose confidential information to each other in connection with R&D contemplated under an R&D Program Agreement ("Confidential Information"). Both parties will use reasonable efforts to prevent the disclosure of the other party's Confidential Information to third parties provided that the recipient party's obligation shall not apply to information that:

 

1. is not disclosed in writing or reduced to writing and marked with an appropriate confidentiality legend within thirty (30) calendar days after disclosure;

 

2. is already in the recipient party's possession at the time of disclosure;

 

3. is or later becomes part of the public domain through no fault of the recipient party;

  

4

  

 

4. is received from a third party having no obligations of confidentiality to the disclosing party;

5. is independently developed by the recipient party; or

 

6. is required by law or regulation to be disclosed.

 

	
b.  

	
In the event that information is required to be disclosed pursuant to subsection (6) immediately above, the party required to make disclosure shall notify the other to allow that party to assert whatever exclusions or exemptions may be available to it under such law or regulation.

 

8. PATENTS, COPYRIGHTS, AND TECHNOLOGY RIGHTS:

 

	
a.  

	
Title to all inventions and discoveries made solely by University inventors resulting from the Research Program shall reside in University; title to all inventions and discoveries made solely by Company inventors shall reside in Company; title to all inventions and discoveries made jointly by University and Company inventors resulting from the Research Program shall reside jointly in University and Company, in accordance with the principles of the United States patent law.

	
b.  

	
Background Intellectual Property (“Background IP”) means property and the legal right therein of either or both parties developed before or independent of this Agreement and any additional agreements arising out of this Agreement, including inventions, patent applications, patents, copyrights, trademarks, mask works, trade secrets and any information embodying proprietary data such as technical data and computer software.

	
c.  

	
This Agreement shall not be construed as implying that either party hereto shall have the right to use Background IP of the other in connection with this Research Program except as otherwise provided hereunder.

 

1. The following Background IP of Company may be used non- exclusively and, except as noted, without compensation by University in connection with research or development activities for this Research Program: Provisional Patent Applications for Cancer (US61/525464) and Alzheimer's and TBI [Tauopathies (PCT/US12/35021)] are further described in Appendix A. Other Background IP of Company will be disclosed as appropriate.

2. The following Background IP of University may be used non-exclusively and, except as noted, without compensation by Company in connection with research or development activities arising from this Research Program (if "none" so state): none.

 

  

5

  

 

	
d.  

	
University will disclose to Company any inventions or discoveries resulting from the Research Program as soon as possible after creation and reduction to practice. Company shall notify University within sixty (60) calendar days of receipt of disclosure whether:

 

1.  Company desires University to file patent applications on any invention, in which case Company shall reimburse all University patent application filing costs, including those for patentability opinions; or

 

2.  Company desires to use its own patent counsel to file patent applications, in which case Company shall be directly responsible for patent application filing but shall obtain University's prior approval of counsel, such approval shall not be unreasonably withheld, and of patent applications; or

3.  Company does not desire that a patent application be filed in which case the rights to such invention shall be handled in accordance with University policies with no further obligation in Company.

	
e.  

	
 In consideration for the Collaborative Agreement and in anticipation of the positive outcomes of University's research, including potential patent license agreements, the Company agrees to pay to University 10% of all gross revenues associated with the sale, license and/or royalties of all products and services directly affiliated with R&D Programs, beginning on the Effective Date. Payments by the Company to the University would be quarterly and would be assured by Company’s audited financial reports using GAAP. However, as a result of the Company being in negotiation with the United States Department of Defense (“U.S. DoD)” to provide the resultant products and services developed from the Research Program at cost, Company will not pay University 10% of any gross revenue derived from the U.S. DoD in the event that an “at cost” agreement is reached between Company and U.S. DoD.

 

	
f.   

	
With respect to inventions for which Company has agreed to file patent application or to reimburse University's costs for filing patent applications, University grants Company an option to negotiate an exclusive or non- exclusive, worldwide, royalty-bearing license to make, use or sell, under any invention or discovery owned wholly or partly by University and made or conceived and reduced to practice during the Term of this Agreement or within six (6) months thereafter and directly resulting from the Research Program. If Company elects an exclusive license, it will include a right to sublicense. Company shall have three (3) months from disclosure of any invention or discovery to notify University of its desire to enter into such a patent license agreement.

 

  

6

  

 

	
g.  

	
Further definitions and details related to the licensing terms, including patent filing and patent prosecution expenses, and a $1,000 documentation fee and those rights subject to Federal Patent Policy, will be addressed in a subsequent patent license agreement, and the parties shall negotiate in good faith for a period not to exceed six (6) months after the notification by Company to enter into a patent license agreement, or such period of time as to which the parties shall mutually agree.

	
h.   

	
If Company and University fail to enter into an agreement during that period of time, the rights to such invention or discovery shall be handled in accordance with University policies with no further obligation to Company.

 

	
i.    

	
University investigators own copyright in their scholarly works. Scholarly works resulting from the Research Program are not subject to the terms of this Section 8.

 

9. LIABILITY

 

	
a.   

	
Company agrees to indemnify and hold harmless System, University, their Regents, officers, agents and employees from any liability, loss or damage they may suffer as a result of claims, demands, costs or judgments against them arising out of the activities to be carried out pursuant to the obligations of this Agreement, including but not limited to the use by Company of the results obtained from the activities performed by University under this Agreement; provided, however, that the following is excluded from Company's obligation to indemnify and hold harmless:

 

1. the negligent failure of University to substantially comply with any applicable governmental requirements; or

 

2. the negligence or willful malfeasance of any Regent, officer, agent or employee of University or System.

 

	
  b.   

	
Both parties agree that upon receipt of a notice of claim or action arising out of the Research Program, the party receiving such notice will notify the other party promptly. Company agrees, at its own expense, to provide attorneys to defend against any actions brought or filed against University, System, their Regents, officers, agents and/or employees with respect to the subject of the indemnity contained herein, whether such claims or actions are rightfully brought or filed; and subject to the statutory duty of The Texas Attorney General, University agrees to cooperate with Company in the defense of such claim or action.

 

  

7

  

 

10. INDEPENDENT CONTRACTOR

 

For the purposes of this Agreement and all services to be provided hereunder, the parties shall be, and shall be deemed to be, independent contractors and not agents or employees of the other party. Neither party shall have authority to make any statements, representations or commitments of any kind, or to take any action which shall be binding on the other party, except as may be expressly provided for herein or authorized in writing under separately negotiated agreements, executed by either party’s authorized officials.

 

11. TERM AND TERMINATION

	
  a.  

	
This Collaborative Agreement will remain in effect for a period identified in Section 2b. of this Agreement unless sooner terminated as provided below.

	
b.   

	
This Collaborative Agreement may be terminated by either Party uponsixty (60) calendar day’s written notice to the other Party and a subsequent agreement to the terms of the termination by the other party. This Collaborative Agreement may also be terminated by either Party in the event of the failure or non-performance of the other Party to comply with the terms of this Agreement with appropriate notification of that failure and the opportunity to correct or rectify the failure in a reasonable timeframe. Both Parties agree to make their best effort to resolve disputes in good faith and avoid litigation between the Parties.

	
c.  

	
Termination or cancellation of this Collaborative Agreement shall not affect the rights and obligations of the parties accrued prior to termination. Upon termination, Company shall pay University for all expenses incurred, committed to be expended, or uncancellable obligations on the R&D Program Agreements.

	
d.  

	
In the event there is at least a 50% change of ownership of Company, the University has the option of continuing or terminating this Collaborative Agreement. If University chooses to terminate this Agreement, ten percent (10%) of the value of the technology represented and derived from the R&D Program Agreements would be paid to the University.  If the methodology to determine the value is not completed within six (6) months, the value will be 100% of the purchase price.

	
e.  

	
In the event that Company does not provide funding for the anticipated R&D Program Agreements within sixty (60) calendar days after receipt of duly issued invoice issued by University authorized Accounting Office, University may at its sole discretion terminate this Collaborative Agreement and all other agreements that may arise out of this Collaborative Agreement by providing written notice of termination for cause to Company.

 

  

8

  

 

	
f.   

	
Provision 8(e) of this Agreement shall extend beyond the termination of this Agreement and shall remain in effect for a total period of twenty-five (25) years from the Effective Date. Additionally, any other provisions of this Agreement which by their nature extend beyond termination shall survive such termination.

 

12. ATTACHMENTS

 

Attachments are incorporated herein and made a part of this Agreement for all purposes.

 

13. GENERAL

 

	
a.  

	
This Agreement may not be assigned by either party without the prior written consent of the other party; provided, however, that subject to the approval of University, which may not be unreasonably withheld, Company may assign this Agreement to any purchaser or transferee of all or substantially all of Company's assets or stock upon prior written notice to University, and University may assign its right to receive payments hereunder.

	
b.  

	
This Agreement constitutes the entire and only agreement between the parties relating to the Research Program, and all prior negotiations, representations, agreements and understandings are superseded hereby. No agreements altering or supplementing the terms hereof may be made except by means of a written document signed by the duly authorized representatives of the parties.

	
c.  

	
Any notice required by this Agreement by Articles 8, 9, or 11 shall be given by prepaid, first class, certified mail, return receipt requested, addressed in the case of University to:

 

The University of Texas at El Paso

Office of Research and Sponsored Projects

Administration Building, Room 209

500 W. University

El Paso, Texas 79968

Phone: 915-747-5680

Attn: Dr. Roberto Osegueda, Vice President for Research 

 

or in the case of Company to:

 

  

9

  

 

	
  

	
Premier Biomedical, Inc.

10805 Fallen Leaf Lane

Port Richey, FL 34668

Phone: (814) 786-8849

Attn: William A. Hartman, CEO

 

or at such other addresses as may be given from time to time in accordance with the terms of this notice provision.

 

	
d.  

	
Notices and other communications regarding the day-to-day administration and operation of this Collaborative Agreement shall be mailed (or otherwise delivered), and addressed in the case of University to:

 

The University of Texas at El Paso

Office of Research and Sponsored Projects

Administration Building, Room 209

500 W. University

El Paso, Texas 79968

Attn: Susan Avena

Email:  savena@utep.edu

Phone: 915-747-7007

 

or in the case of Company to: Premier Biomedical, Inc.

10805 Fallen Leaf Lane

Port Richey, FL 34668

Email: williamhartman@aol.com

Phone: (814) 786-8849

 

	
e.   

	
Notices and other communications regarding the day-to-day administration and operation of R&D Program Agreements shall be mailed (or otherwise delivered) and addressed in the case of University to:

 

The University of Texas at El Paso

Office of Research and Sponsored Projects

Administration Building, Room 209

500 W. University

El Paso, Texas 79968

Attn: Teresa Almengor Email: talmengor@utep.edu Phone: 915-747-5745

 

or in the case of Company to:

 

  

10

  

 

	
   

	
Premier Biomedical, Inc.

10805 Fallen Leaf Lane

Port Richey, FL 34668

Email:williamhartman@aol.com

Phone: (814} 786-8849

 

	
e.   

	
This Agreement shall be governed  by, construed, and enforced in accordance with the Laws and Constitution of the State of Texas.

 

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by their duly authorized representatives.

 

	PREMIER BIOMEDICAL,INC.	 	THE UNIVERSITY OF TEXAS AT EL PASO	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	/s/ William A. Hartman	 	/s/ Richard Adauto	 
	William A. Hartman	 	Richard Adauto	 
	CEO	 	Executive Vice President	 
	Date: 05/07/12	 	Date: 05/09/12	 

 

 

  

11

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]